Private equity firm Permira agreed to acquire Neuraxpharm, a European specialty pharmaceutical company focused on the treatment of the central nervous system, from funds advised by Apax Partners. Financial terms were not disclosed. "We are very excited to join forces with Neuraxpharm. The team led by CEO Dr. Jörg-Thomas Dierks has built one of the most relevant European players in the CNS field. With our longstanding global track-record in successfully transforming market leaders and our proven expertise in the healthcare sector, the Permira funds will back Neuraxpharm to reach the next level of growth. Our joint goal is to create the leading European CNS specialty platform with further acquisitions and strong organic growth. This transaction also marks an excellent start for our strengthened DACH healthcare team, led by Florian Kreuzer who joined Permira a year ago," Jörg Rockenhäuser, Permira Head of DACH.